Call us Today! 201-728-8809 | | Contact | About |
   


Barcode Five Rights System

Use Barcode to prevent medication errors

ADERS ® is a barcode point of care, (BPOC), solution

Practical Compliance Solutions, Corp. helps care facilities reduce risk at the patient's bedside. Our five rights barcode solution is the easiest to implement. Our barcode point of care system can help prevent medication errors in hospitals, long term care facilities, and assisted living communities.

ADERS ® is our barcode solution for the healthcare industry. It helps eliminate medication errors by allowing caregivers to scan NDC barcodes at the patient's bedside, verifying right patient, right drug, right time, right dose, and right route of administration. For more information click the products menu or send us a web request from our Contact menu. Ask for a DEMO CD. It is the full product that is licensed for an evaluation period.

We are offering a 30 day no-obligation free trial of the ADERS ® software. Care facilities can easily determine if ADERS ® is right for them by using the software as a pilot for a single unit or ward. Click here to download a Microsoft Project plan showing how you can implement a five rights point of care barcode pilot in less than a week. If you Don't own MS Project 2003, then here is a PDF copy just to see.... Download Adobe PDF Data Sheet

View a PowerPoint Presentation of ADERS ®.

Get The Latest Patient Safety and Drug Safety Updates from the FDA

FDA Press Releases RSS Feed

FDA confirms elevated levels of belladonna in certain homeopathic teething products
Fri, 08/23/2019 - 14:01

The U.S. Food and Drug Administration announced today that its laboratory analysis found inconsistent amounts of belladonna, a toxic substance, in certain homeopathic teething tablets, sometimes far exceeding the amount claimed on the label. The agency is warning consumers that homeopathic teething tablets containing belladonna pose an unnecessary risk to infants and children and urges consumers not to use these products.

FDA proposes new, risk-based enforcement priorities to protect consumers from potentially harmful, unproven homeopathic drugs
Fri, 08/23/2019 - 14:01

Today, the U.S. Food and Drug Administration proposed a new, risk-based enforcement approach to drug products labeled as homeopathic. To protect consumers who choose to use homeopathic products, this proposed new approach would update the FDA’s existing policy to better address situations where homeopathic treatments are being marketed for serious diseases and/or conditions but where the products have not been shown to offer clinical benefits. It also covers situations where products labeled as homeopathic contain potentially harmful ingredients or do not meet current good manufacturing practices.

FDA warns company for putting consumers at risk with drug manufacturing data integrity violations
Tue, 08/20/2019 - 11:22

The FDA posted a warning letter for significant current good manufacturing practice violations, including data integrity issues.

Statement on new results demonstrating continued success of the agency’s youth smoking prevention efforts and significant public health cost savings
Tue, 08/20/2019 - 09:22

A new study in the American Journal of Preventive Medicine highlights the continued success and impact the FDA’s “The Real Cost” campaign has had on youth smoking initiation.

FDA approves new antibiotic to treat community-acquired bacterial pneumonia
Mon, 08/19/2019 - 15:05

The FDA approved Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia.

FDA warns consumers about the dangerous and potentially life threatening side effects of Miracle Mineral Solution
Mon, 08/19/2019 - 12:36

The FDA is warning consumers not to purchase or drink Miracle Mineral Solution, a product sold online as a medical treatment due to a recent rise in reported health issues.

FDA approves new device to improve symptoms in patients with advanced heart failure
Mon, 08/19/2019 - 09:45

FDA approves new device to improve symptoms in patients with advanced heart failure

FDA expands indication for several transcatheter heart valves to patients at low risk for death or major complications associated with open-heart surgery
Fri, 08/16/2019 - 12:03

FDA expands indication for several transcatheter heart valves to patients at low risk for death or major complications associated with open-heart surgery.

FDA approves first of its kind device to treat pediatric patients with progressive idiopathic scoliosis
Fri, 08/16/2019 - 10:32

FDA approves first of its kind device to treat pediatric patients with progressive idiopathic scoliosis

FDA approves treatment for patients with rare bone marrow disorder
Fri, 08/16/2019 - 10:05

FDA approves treatment for adult patients with certain types of myelofibrosis.

FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor
Thu, 08/15/2019 - 15:41

FDA approves third cancer treatment based on a common biomarker across different types of tumors rather than the location in the body where the tumor originated

FDA proposes new required health warnings with color images for cigarette packages and advertisements to promote greater public understanding of negative health consequences of smoking
Thu, 08/15/2019 - 10:02

FDA has issued a proposed rule to require new health warnings on cigarette packages and in ads to promote greater public understanding of the negative health consequences of smoking.

FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs
Wed, 08/14/2019 - 12:53

FDA approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis of the lungs.

FDA announces comprehensive regenerative medicine policy framework
Fri, 08/09/2019 - 15:55

FDA announces comprehensive regenerative medicine policy framework to spur innovation, efficient access to potentially transformative products, while ensuring safety and efficacy.

FDA sends warning to company for marketing dangerous unapproved stem cell products that put patients at risk and puts other stem cell firms, providers on notice
Fri, 08/09/2019 - 15:35

FDA sends warning letter to Genetech, Inc. and letters to other companies to reiterate the FDA’s compliance and enforcement policy regarding stem cells.

FDA notifies four companies to remove 44 flavored e-liquid and hookah tobacco products from the market for not having required marketing authorization
Thu, 08/08/2019 - 10:25

FDA has notified four firms that 44 flavored e-liquid and hookah tobacco products do not have the required marketing authorization, and thus cannot be legally sold in the U.S.

Statement on data accuracy issues with recently approved gene therapy
Tue, 08/06/2019 - 13:20

Statement by Peter Marks, M.D., Ph.D., director of FDA’s Center for Biologics Evaluation and Research, on data accuracy issues with recently approved gene therapy

FDA statement on court ruling related to compounded bulk drug substances and the agency’s ongoing efforts to implement its compounding authorities
Tue, 08/06/2019 - 11:54

A U.S. District Court judge in Washington, D.C. issued a decision that upheld FDA’s interpretation of clinical need regarding the bulk substances that may be used by outsourcing facilities in drug compounding.

Statement on new guidance for the declaration of added sugars on food labels for single-ingredient sugars and syrups and certain cranberry products
Sun, 08/04/2019 - 02:03

This is a statement regarding the FDA’s new guidance for the declaration of added sugars on food labels for single-ingredient sugars and syrups and certain cranberry products.

FDA approves first therapy for rare joint tumor
Fri, 08/02/2019 - 14:50

FDA approves first therapy for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT)

Food and Drugs Administration--Recalls/Safety Alerts

Altaire Pharmaceuticals, Inc. Issues Voluntary Recall Of Veterinary Ophthalmic Products
Fri, 08/23/2019 - 13:08

Altaire Pharmaceuticals, Inc., announces today that it is voluntarily recalling the Veterinary ophthalmic drug products and lots, within expiry, identified below. This recall is only for the specific lots listed. No other lots are being recalled.

Allergy Alert for Undeclared Egg in “Decorated Red Apple Cookies” Issued by Southern Pacific Whole Foods Market Stores
Thu, 08/22/2019 - 18:22

“Decorated Red Apple Cookies” are being voluntarily recalled by Southern Pacific Whole Foods Market stores because they may contain undeclared egg

Voluntarily Recalls Grained Salmon Caviar 95g Because of Possible Health Risk
Thu, 08/22/2019 - 11:10

The product with these codes may have the potential to be contaminated with Clostridium botulinum, a bacterium which can cause life-threatening illness or death. Consumers are warned not to use the product even if it does not look or smell spoiled.

AWERS, Inc. Recalls Grained Salmon Caviar 95g Because of Possible Health Risk
Wed, 08/21/2019 - 20:45

AWERS, Inc. of Bellevue, WA is recalling Grained Salmon Caviar 95g (Sockeye Salmon Caviar) with “BEST BEFORE OCT 07 2020”, because it has the potential to be contaminated with Clostridium botulinum, a bacterium which can cause life-threatening illness or death.

FDA Cautions Pet Owners Not to Feed Texas Tripe Inc. Raw Pet Food Due to Salmonella, Listeria monocytogenes
Mon, 08/19/2019 - 13:05

FDA is cautioning pet owners not to feed pets certain lots of Texas Tripe Inc. raw pet food after samples tested positive for Salmonella, Listeria monocytogenes.

Dog Goods USA LLC To Conduct A Voluntary Recall of Chef Toby Pig Ears Treats Because of Possible Salmonella Health Risk
Mon, 08/19/2019 - 09:36

Dog Goods USA LLC to conduct a voluntary recall of Chef Toby Pig Ears Treats because of possible salmonella health risk.

Pfizer Inc. Issues a Voluntary Nationwide Recall for 2 Lots of RELPAX® (eletriptan hydrobromide) 40 mg Tablets Due to Potential Microbiological Contamination of Non-Sterile Products
Thu, 08/15/2019 - 10:02

Pfizer Inc. is voluntarily recalling RELPAX® (eletriptan hydrobromide) 40 mg tablets, lots AR5407 and CD4565, to the Patient level. Pfizer Inc. initiated this recall because these product lots may not meet Pfizer’s in-house microbiological specification for the potential presence of Genus Pseudomona

Dole Fresh Vegetables Announces Precautionary Limited Recall of Baby Spinach
Fri, 08/09/2019 - 19:22

The products being recalled are 6 oz Dole Baby Spinach bag, Lot code W20308A (UPC code 0-71430-00964-2), and 10 oz Dole Baby Spinach clamshell, Lot code W203010 (UPC code 0-71430-00016-8), both with Use-by dates of 08-05-2019, due to a possible health risk from Salmonella

Ridge Properties LLC DBA Pain Relief Naturally Issues Voluntary Nationwide Recall of PRE-TAT , Superior Pain and Itch Relief, and Soothing Sore Relief Cream and Gel Products Due to Microbiological Contamination and Superpotency
Thu, 08/08/2019 - 20:40

Ridge Properties LLC DBA Pain Relief Naturally is voluntarily recalling 4 lots of 4% lidocaine topical cream & liquid gel products sold at the consumer level. FDA analysis has found these products to have microbiological contamination and the potency is higher than the labeled amount for lidocaine.

Cargill Conducts Voluntary Recall of Select Southern States® Feed Due to High/Excessive/or Elevated Aflatoxin Levels
Thu, 08/08/2019 - 14:45

Cargill’s animal nutrition business is conducting a voluntary recall of select Southern States® feed due to aflatoxin levels that exceed FDA’s action levels. The affected products, which were manufactured and sold in the eastern United States, were removed from retail shelves throughout February

Pregel America, Inc. Issues Allergy Alert on Undeclared Milk in Lemon 50
Fri, 08/02/2019 - 17:49

PreGel America, Inc. of Concord, North Carolina is voluntarily recalling a single lot of Lemon 50, a powdered flavoring. The product is being recalled due to the possible presence of undeclared milk in the product.

The Lennox Intl Inc is Voluntary Recalling Natural Pig Ears on July 26, 2019
Fri, 08/02/2019 - 17:06

The Lennox Intl Inc located in Edison NJ, is voluntary recalling its Natural Pig ears because they have the potential to be contaminated with Salmonella.

Expanded - The Lennox Intl Inc is Voluntary Recalling Natural Pig Ears on July 26, 2019
Fri, 08/02/2019 - 17:05

The Lennox Intl Inc located in Edison NJ, is expanding its voluntary recall of its Natural Pig ears because they have the potential to be contaminated with Salmonella.

Bimbo Bakeries USA Voluntary Recall of Entenmann’s Little Bites Cookies Due to Potential Presence of Plastic Pieces
Fri, 08/02/2019 - 00:55

Bimbo Bakeries USA, Inc. has initiated a voluntary recall of Entenmann’s Little Bites Soft Baked Cookies (5 pack Mini Chocolate Chip variety) due to the potential presence of visible, blue plastic pieces in the individual packaging pouch.

Ruleau Brothers Issues Allergy Alert On Undeclared Eggs, Soy, and Anchovies in "Door County Whitefish Smoked Whitefish Pate"
Thu, 08/01/2019 - 14:32

Ruleau Brothers Inc. of Stephenson, MI, is recalling its 8 ounce containers of "Door County Whitefish Smoked Whitefish Pate" because they may contain undeclared allergens of Egg, Soy, and Anchovies. People who have allergies to Eggs, Soy, and Anchovies run the risk of serious or life-threatening all

Dole Fresh Vegetables Announces Voluntary Withdrawal for Salads
Wed, 07/31/2019 - 16:46

Dole Fresh Vegetables, Inc., is temporarily suspending operations at its Springfield, Ohio production facility, and is voluntarily withdrawing from the market all Dole-branded and private label packaged salads processed at that location

The Cookie Dough Cafe Issues Allergy Alert on “Chocolate Chip Chilled Gourmet Edible Cookie Dough Bar" Due to Possible Peanuts in Product
Wed, 07/31/2019 - 11:05

JuJu Bakes, LLC, DBA The Cookie Dough Cafe of Bloomington, IL is recalling 15 cases of 1.6 ounce Chocolate Chip Chilled Gourmet Edible Cookie Dough Bars, because they may contain peanuts.

Altaire Pharmaceuticals, Inc. Issues Voluntary Recall of Multiple Ophthalmic Products Sold at Wal Mart
Mon, 07/29/2019 - 16:35

As a precautionary measure, Altaire is initiating the recall due to management concerns regarding the sufficiency of Quality Assurance controls over critical systems in the manufacturing facility

Altaire Issues Correction to 07.03.2019 Recall Announcement for OTC Products Sold at Wal-Mart
Mon, 07/29/2019 - 16:33

Altaire Pharmaceuticals, Inc., announces today that it is correcting its July 3, 2019 Announcement of a Voluntary Recall for Over-the-Counter (OTC) drug products and lots, within expiry, sold at Wal-Mart during the time period as indicated in the tables below.

Williams Foods LLC Initiates a Voluntary Recall of Taco Seasoning Product Due to Possible Presence of Salmonella Contamination
Fri, 07/26/2019 - 07:26

These items contain cumin spice involved in a recall initiated by our supplier, Mincing Spice Co. Mincing has issued a recall for a specific lot of cumin they produced because a sample from that lot was tested by one of Mincing's customers and was found to be potentially contaminated with Salmonella

What's New: Drugs RSS Feed

Altaire Pharmaceuticals, Inc. Issues Voluntary Recall Of Veterinary Ophthalmic Products
Fri, 08/23/2019 - 13:08

Altaire Pharmaceuticals, Inc., announces today that it is voluntarily recalling the Veterinary ophthalmic drug products and lots, within expiry, identified below. This recall is only for the specific lots listed. No other lots are being recalled.

Developing Real-World Data and Evidence to Support Regulatory Decision-Making - 10/03/2019 - 10/03/2019
Fri, 08/23/2019 - 13:05

This is a meeting webpage announcing a conference on Developing Real-World Data and Evidence to Support Regulatory Decision-Making. This conference will bring together experts to examine topics in RWD and RWE.

All Guidances for Drugs
Fri, 08/23/2019 - 12:20

All Guidances for Drugs

Hypnotic Drugs--Clinical Evaluation
Fri, 08/23/2019 - 12:10

Clinical/Medical

Complex Innovative Trial Designs Pilot Program
Fri, 08/23/2019 - 12:05

As displayed in the Federal Register notice on August 1, 2018, FDA is conducting a Complex Innovative Designs (CID) Pilot Meeting Program to support the goal of facilitating and advancing the use of complex adaptive, Bayesian, and other novel clinical trial designs, as highlighted in the sixth iteration of the Prescription Drug User Fee Act (PDUFA VI).

Identification of Medicinal Products (IDMP)
Fri, 08/23/2019 - 09:45

IDMP is a suite of five standards developed within the International Organization for Standardization (ISO).

Drug Shortages: Additional News and Information
Fri, 08/23/2019 - 09:00

Drug Shortages: Additional News and Information

Antimicrobial Resistance Information from FDA
Fri, 08/23/2019 - 08:20

Antimicrobial resistance (AMR)—the ability of a microorganism (bacteria, virus, fungi, parasite) to resist the effects of a drug—is a serious, complex and costly public health problem. Learn what FDA is doing to address AMR.

What's New Related to Drugs
Fri, 08/23/2019 - 07:40

Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.

Speech by Dr. Amy Abernethy at the National Coordinator for Health IT Third Interoperability Forum - 08/22/2019
Thu, 08/22/2019 - 17:30

Remarks by Dr. Amy Abernethy, Principal Deputy, FDA, at the Office of the National Coordinator for Health IT Third Interoperability Forum in Washington, DC. on August 22, 2019

Drug Trials Snapshots: NUBEQA
Thu, 08/22/2019 - 15:21

Drug Trial Snapshot

FDA Drug Safety Communication: FDA to evaluate increased risk of heart-related death and death from all causes with the gout medicine febuxostat (Uloric)
Thu, 08/22/2019 - 15:00

The U.S. Food and Drug Administration (FDA) is warning that preliminary results from a safety clinical trial show an increased risk of heart-related death with febuxostat (Uloric) compared to another gout medicine called allopurinol. We required the Uloric drug manufacturer, Takeda Pharmaceuticals, to conduct this safety study when we approved the medicine in 2009. Once we receive the final results from the manufacturer, we will conduct a comprehensive review and will update the public with any new information.

Biomarker Qualification Submissions
Thu, 08/22/2019 - 14:40

The FDA CDER Biomarker Qualification Program invites submitters who have a biomarker qualification project accepted into the Program to voluntarily provide general information about their project and contact information to be posted on the FDA’s public web site. The table below lists submissions that are currently in the qualification process. Submissions listed here are only for those which submitters have agreed to make public. The table is updated on a quarterly basis and provides information on the biomarker qualification project and submitter contact information.

2019 Drug Safety Communications
Thu, 08/22/2019 - 14:20

2019 Drug Safety Communications

September 18, 2019: Meeting of the Nonprescription Drugs Advisory Committee Meeting Announcement - 09/18/2019 - 09/18/2019
Thu, 08/22/2019 - 14:10

September 18, 2019: Meeting of the Nonprescription Drugs Advisory Committee Meeting Announcement

General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products Guidance for Industry
Thu, 08/22/2019 - 13:50

Guidance for Industry : Clinical Pharmacology

MedWatch: The FDA Safety Information and Adverse Event Reporting Program
Thu, 08/22/2019 - 13:06

MedWatch home page

Patient Engagement Collaborative
Thu, 08/22/2019 - 12:30

The Patient Engagement Collaborative (PEC) is an advancement in FDA’s efforts to strengthen its relationship with patient communities and is being coordinated by the FDA’s Patient Affairs Staff (PAS) in the Office of Clinical Policy and Programs (OCPP).

2019 Meeting Materials, Arthritis Advisory Committee
Thu, 08/22/2019 - 12:25

2019 Meeting Materials, Arthritis Advisory Committee

October 30, 2019: Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee Meeting Announcement - 10/30/2019 - 10/30/2019
Thu, 08/22/2019 - 12:05

October 30, 2019: Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee Meeting Announcement

Whats New Vaccines Blood Biologics RSS Feed

Preparation of IDEs and INDs for Products Intended to Repair or Replace Knee Cartilage
Fri, 08/23/2019 - 11:10

Guidance for Industry: Preparation of IDEs and INDs for Products Intended to Repair or Replace Knee Cartilage, CBER, Biologics

VAXELIS
Fri, 08/23/2019 - 09:45

VAXELIS is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae (H. influenzae) type b. VAXELIS is approved for use as a 3 dose series in children 6 weeks through 4 years of age (prior t

What’s New for Biologics
Fri, 08/23/2019 - 09:35

Latest news from the Center for Biologics Evaluation and Research

Antimicrobial Resistance Information from FDA
Fri, 08/23/2019 - 08:20

Antimicrobial resistance (AMR)—the ability of a microorganism (bacteria, virus, fungi, parasite) to resist the effects of a drug—is a serious, complex and costly public health problem. Learn what FDA is doing to address AMR.

Speech by Dr. Amy Abernethy at the National Coordinator for Health IT Third Interoperability Forum - 08/22/2019
Thu, 08/22/2019 - 17:30

Remarks by Dr. Amy Abernethy, Principal Deputy, FDA, at the Office of the National Coordinator for Health IT Third Interoperability Forum in Washington, DC. on August 22, 2019

Draft Recommended Methods for Evaluating Potency, Specificity, and Reactivity of Anti-Human Globulin
Thu, 08/22/2019 - 15:25

Draft Recommended Methods for Evaluating Potency, Specificity, and Reactivity of Anti-Human Globulin, cber, biologics, blood

Draft Points to Consider in the Design and Implementation of Field Trials for Blood Grouping Reagents and Anti-Human Globulin
Thu, 08/22/2019 - 15:21

Draft Points to Consider in the Design and Implementation of Field Trials for Blood Grouping Reagents and Anti-Human Globulin , CBER, biologics

Draft Recommended Methods for Blood Grouping Reagents Evaluation
Thu, 08/22/2019 - 15:20

Draft Recommended Methods for Evaluating Potency, Specificity, and Reactivity of Anti-Human Globulin, CBER, Biologics

Donors of Blood and Blood Components: Notification of Donor Deferral, Small Entity Compliance Guide
Thu, 08/22/2019 - 14:50

The Food and Drug Administration (FDA) has prepared this guidance in accordance with section 212 of the Small Business Regulatory Enforcement Fairness Act of 1996 (Public Law 104-121).

Recommendations for Management of Donors at Increased Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Group O Infection
Thu, 08/22/2019 - 14:50

We, the Food and Drug Administration (FDA), are providing you, blood and plasma establishments, with a revised list of countries that should be included in questions for identifying donors at increased risk for HIV-1 group O infection.

Availability of FDA’s eSubmitter Program for Regulatory Submissions from Licensed Blood Establishments
Thu, 08/22/2019 - 14:40

We, FDA, the Center for Biologics Evaluation and Research (CBER), are announcing to you, licensed blood establishments that collect Whole Blood and blood components, including Source Plasma, the availability of CBER’s eSubmitter Program (eSubmitter), an electronic submissions program.

Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture
Thu, 08/22/2019 - 14:36

This is the Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture; Final Guidance.

Requalification of Donors Previously Deferred for a History of Viral Hepatitis after the 11th Birthday
Thu, 08/22/2019 - 14:26

We, FDA, are issuing this guidance to provide you, establishments that collect Whole Blood or blood components intended for transfusion or for further manufacture, including Source Plasma and Source Leukocytes, with recommendations for a requalification method under Title 21 of the CFR.

General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products Guidance for Industry
Thu, 08/22/2019 - 13:50

Guidance for Industry : Clinical Pharmacology

Perspectives on In Vitro Diagnostic Devices Regulated by the Office of Blood Research and Review; Public Workshop - 07/15/2019 - 07/16/2019
Thu, 08/22/2019 - 13:25

The purpose of this workshop is to provide an overview of key elements of regulatory submissions for these devices, and to facilitate education and communication between manufacturers and sponsors of these devices and the divisions in CBER that regulate them.

MedWatch: The FDA Safety Information and Adverse Event Reporting Program
Thu, 08/22/2019 - 13:06

MedWatch home page

Patient Engagement Collaborative
Thu, 08/22/2019 - 12:30

The Patient Engagement Collaborative (PEC) is an advancement in FDA’s efforts to strengthen its relationship with patient communities and is being coordinated by the FDA’s Patient Affairs Staff (PAS) in the Office of Clinical Policy and Programs (OCPP).

How do I request a Patient Listening Session?
Thu, 08/22/2019 - 11:51

Learn about how to request a Listening Session with the FDA to share your experience with a disease or condition.

Guidance for Industry for the Evaluation of Combination Vaccines for Preventable Diseases: Production, Testing and Clinical Studies
Wed, 08/21/2019 - 16:55

Guidance for Industry for the Evaluation of Combination Vaccines for Preventable Diseases: Production, Testing and Clinical Studies, guideline, combination, vaccine, disease, guidance document, CBER, Biologics

Guidance and Other Information of Special Interest to MCM Stakeholders
Wed, 08/21/2019 - 16:51

Information of particular interest to sponsors/applicants of medical countermeasures to treat, prevent, diagnose, and detect chemical, biological, radiological, and nuclear threats and emerging infectious diseases


Here are some headlines supporting the benefits of a system like ADERS ®:



See how to prevent medication errors with bar codes using ADERS. Get your free pilot started today.




Corporate Headquarters

Practical Compliance Solutions
One Orient Way - Suite F156 Rutherford, NJ 07070
Phone: 201-728-8809


40.827731 N 74.101029 W
Connect With Us


Share




© 2002 - 2019 - Copyright Practical Compliance Solutions - All rights reserved